Two decades after a breast cancer vaccine trial, every participant is still alive—an astonishing result for metastatic ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.

New research suggests that a breast cancer vaccine developed decades ago may have triggered a lasting immune memory response that can now be significantly boosted by a newly developed antibody.

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

The preventive immunization Nous-209 works in an initial trial with patients who have 17 times the risk of developing tumors compared to the general population ...

He's lost his father, a brother, aunts, uncles and extended family members to cancer — many of them in their 30s and 40s.